Medication Management
Elevating Health Care Through Precision Medicine
Medication management is a challenge for healthcare providers who treat patients with chronic illness, behavioral and mental health conditions, and during and after care transition.
Medication discrepancies, nondisclosure and nonadherence put patients at increased risk of clinical deterioration, adverse drug reactions (ADRs), drug-drug interactions, hospitalization and mortality. Additionally, unseen genetic factors may affect response to drugs, including efficacy and toxicity, that can lead to inappropriate therapies, “prescribing cascades,” ADRs and progression of disease.
When prescribed medications don’t work as expected for your patient, it can be difficult to determine the exact cause.
Navis offers two medication management solutions to help providers make safer and more informed treatment decisions
Navis offers a proprietary Polypharmacy Testing solution that targets more than 120 drugs and metabolites for prescription and over-the-counter medications, including those commonly used for the treatment of chronic pain, psychiatric, cardiac, nephrology and diabetic conditions, to help identify potential nonadherence, contraindications and dangerous drug interactions.
If medication failure can’t be explained by nonadherence, contraindications or drug-drug interactions, Pharmacogenetic (PGx) Testing is an ideal testing option that provides insights into a patient’s genetic variations that affect metabolism of drugs in 18 drug classes, including pain, psychiatric and cardiac, and helps to develop more personalized, effective treatments, reduce trial-and-error prescribing and ADRs, and improve medication adherence and outcomes.
Improved Patient Safety, Treatment Adherence and Patient Outcomes
46%
of prescription drug users tell their physician about any OTC drugs they take1
75%
likelihood of an ADR for people who consume 5 or more medications concurrently2
90%
of people likely carry at least one actionable PGx variant in one of five well-established drug-gene interactions3
30%
decrease in clinically relevant ADRs when drug prescriptions are guided by PGx4